A Phase II , Open-Label, Extension Study to Assess the Safety and Efficacy of NS-065/NCNP-01 in Boys with Duchenne Muscular Dystrophy (DMD)

Administered By

Neurology

Awarded By

NS Pharma, Inc.

Contributors

Smith, Edward Clinton Principal Investigator

Start/End

August 29, 2017 - December 31, 2020